Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer

Far Eastern Memorial Hospital80 enrolled

Overview

This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer

Interventions

ChemotherapyDRUG

Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy Exclusion Criteria: * women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)

Locations (1)

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital

Banqiao District, New Taipei, Taiwan

Outcomes

Primary Outcomes

RFS

Recurrence free survival

Time frame: the time interval from the date of surgery or the start of chemotherapy to clinically defined recurrence, disease progression, death from any cause or last follow-up

Overall Survival

Time frame: the time interval from the date of surgery or the start of chemotherapy to the date of death from any cause or last follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.